Effect of Chronic Use of Proton Pump Inhibitors on Bone Mineral Density

Shandookh, Qusay Jassam; Albedri, Khudair; Abdullateef, Nada Naji

doi:10.52573/ipmj.2021.174635

	Effect of Chronic Use of Proton Pump Inhibitors on Bone Mineral Density
Iraqi Postgraduate Medical Journal
Article 16, Volume 21, Issue 2, 2022, Pages 236-242 PDF (215.43 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2021.174635
Authors
Qusay Jassam Shandookh¹; Khudair Albedri²; Nada Naji Abdullateef³
¹Clinical Pharmacy/ Baghdad Teaching Hospital/ Medical City/ Iraq.
²Internal Medicine, Rheumatology and Medical Rehabilitation/College of Medicine, University of Baghdad, Baghdad-Iraq.
³Pharmacology and Toxicology/ College of Pharmacy / University of Baghdad /Baghdad-Iraq
Abstract
BACKGROUND: Proton pump inhibitors (PPIs) are widely used drugs for the treatment of many diseases. Prolonged use was believed to have an effect on bone mineral metabolism. OBJECTIVE: To investigate the effect of PPIs on bone mineral density and to identify risk factors affecting bone mineral density among users of PPIs. PATIENTS AND METHODS: A cross sectional study was conducted in Rheumatology Consultancy Clinic of Baghdad Teaching Hospital /Baghdad Medical City during the period from 1st of November, 2017 to 31st of October, 2018 on convenient sample of 100 patients were selected; first group was 50 PPI users and 50 PPI non-users. The bone mineral density of patients was assessed using dual energy x-ray absorptiometry (DXA) scan. RESULTS: A significant reduction in serum calcium, vitamin D and serum inorganic phosphorus levels of PPIs users with elevated level of alkaline phosphatase activity. All scores of DXA scan like T-scores L2-L4, Z-scores L2-L4 and total scores were significantly reduced among PPIs users in comparison to PPIs-non users (P<0.05). CONCLUSION: The proton pump inhibitors have a profound effect on bone mineral density and long term use of proton pump inhibitors is commonly related with osteoporosis and osteopenia development of lumbar spines.
Keywords
ppi; dexa scan; calcium.vitamine d; alp.phophorous

References
Yanagihara GR, de Paiva AG, Neto MP, Torres LH, Shimano AC, Louzada MJQ, et al. Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone. Revista Brasileira de Ortopedia 2015; 50:232-38. Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 2009; 104(Suppl 2):S2–S4. Lau AN, Tomizza M, Wong-Pack M, Papaioannou A, Adachi JD. The relationship between long-term proton pump inhibitor therapy and skeletal frailty. Endocrine 2015; 49:606-10. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179:319–26. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial. Am J Med 2005; 118:778–81. Yamasaki Y, Fujimura T, Oyama K, Higashi Y, Hirose A, Tsukada T, et al. Effects of rabeprazole on bone metabolic disorders in a gastrectomized rat model. Biomedical Reports 2016; 5:118-24. Couris RR, Dinsmore S, Grams M-K. Osteoporosis; In Zeind CS, Carvalho MG. Applied therapeutics: The clinical use of drugs. Wolters Kluwer, Philadelphia USA 2018:2269. Dial S. Use of gastric acid-suppressive agents and the risk of community acquired Clostridium difficile associated disease. JAMA 2005; 294:2989–95. Howell MD. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170:784–90. 10. Rozgony NR. Vitamin B (12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: 79 could a cyanocobalamin nasal spray be beneficial? J Nutr Elder 2010; 29:87–99. 11. Sampathkumar K, Ramalingam R, Prabakar A, Abraham A. Acute interstitial nephritis due to proton pump inhibitors. Indian J Nephrol 2013; 23(4):304-307. 12. Lau AN, Tomizza M, Wong-Pack M, Papaioannou A, Adachi JD. The relationship between long-term proton pump inhibitor therapy and skeletal frailty. Endocrine 2015; 49:606-10. 13. Yang X-Y. Chronic proton pump inihibitor therapy and calcium metabolism. Curr Gastroenterol Rep 2012; 14:473-79. 14. Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Ziegler TE, Penniston KL, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010; 25:2786-95. 15. Costa-Rodrigues J, Reis S, Teixeira S, Lopes S, Fernandes MH. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J 2013; 280:5052-64. 16. Jo Y, Park E, Ahn SB, Jo YK, Son B, Kim SH, et al. A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study. Gut Liver 2014; 9:607-14. 17. Ozdil K, Kahraman R, Sahin A, Calhan T, Gozden EH, Akyuz U, et al. Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int 2013; 33:2255-60. 18. Rexhepi S, Bahtiri E, Rexhepi M, Sahatciu-Meka V, Rexhepi B. Association of Body Weight and Body Mass Index with Bone Mineral Density in Women and Men from Kosovo. Mater Sociomed 2015; 27:259-62. 19. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep 2010; 12:448-57. 20. Al-Zahrany AA, AL Mourgi M. Risk of Osteoporosis and Osteopenia in Patients with Prolonged Use of Proton Pump Inhibitors. The Egyptian Journal of Hospital Medicine 2016; 65: 643- 647. 21. Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis 2014; 6:185-202.
Statistics Article View: 318 PDF Download: 201